Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-synuclein seeding activity
Authors:
- 13 September 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (9) , 1-10
Abstract
Objective Parkinson’s disease (PD) associated with mutations in the LRRK2 gene exhibits considerable pathological heterogeneity and may not present with Lewy body pathology. The α-Syn seed amplification assay (SAA) performed on cerebrospinal fluid (CSF) has emerged as a reliable in vivo biomarker of α-Syn aggregation. In this study, we aim to investigate the longitudinal trajectories of striatal dopaminergic imaging in LRRK2 PD patients stratified by CSF α-Syn SAA status. Methods Data were obtained from the Parkinson’s Progression Markers Initiative. CSF α-Syn aggregation was assessed using SAA. Striatal DAT-specific binding ratios (SBR) were quantified using [123I] FP-CIT SPECT at baseline, year 2, and year 4. Results At baseline, the α-Syn SAA-negative LRRK2 PD group exhibited higher DAT binding in the contralateral putamen and ipsilateral putamen compared to the SAA-positive group with comparable disease duration. Longitudinally, linear mixed-effects models demonstrated that the α-Syn SAA-negative LRRK2 PD maintained significantly higher DAT binding in both the contralateral and ipsilateral putamen over time. A significant group × time interaction was identified in the contralateral caudate, suggesting a slower rate of DAT loss in the α-Syn SAA-negative group. Sensitivity analyses restricted to participants with complete baseline and follow-up imaging data largely confirmed the main LMEM findings. Conclusions The observed differences in striatal dopaminergic degeneration between LRRK2 PD patients with and without detectable CSF α-synuclein aggregates may reflect region-specific vulnerability to underlying pathological processes. Our findings support the utility of CSF α-Syn SAA status as both a diagnostic and prognostic biomarker in LRRK2 PD.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82401745, 82471271)
- The Parkinson’s Progression Markers Initiative
This publication has 43 references indexed in Scilit:
- Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson DiseaseJAMA Neurology, 2015
- LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?Journal of Neuroinflammation, 2014
- LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson’s DiseaseExperimental Neurobiology, 2013
- A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's diseaseQJM: An International Journal of Medicine, 2010
- Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype CorrelationNeurodegenerative Diseases, 2010
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- α-Synuclein in Lewy bodiesNature, 1997
- [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988